Orient Pharma Co (ROCO:4166) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4166 Orient Pharma Co Ltd ROCO:4166
62 GF Score
Price NT$26.20
GF Value NT$45.37
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orient Pharma Co FFO per Share?

FFO per Share only applies to REITs.

ROCO:4166
62GF Score
Orient Pharma Co Ltd ROCO:4166
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$26.20 is trading 42.3% below its estimated GF Value™ of NT$45.37. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • FFO per Share:
  • GF Value™: NT$45.37 vs. price of NT$26.20 (42.3% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
62GF Score

Get the complete analysis for ROCO:4166

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.20
Price
NT$45.37
GF Value